Rabab Gaafar

Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

Jan P. van Meerbeeck, Rabab Gaafar, Christian Manegold et al. · Journal of Clinical Oncology · 2005 · 621 citations · Full text

Medicine, Oncology, Pharmacology +14

Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975

Egbert F. Smit, J.P.A.M van Meerbeeck, P. Lianes et al. · Journal of Clinical Oncology · 2003 · 352 citations

Medicine, Oncology, Pharmacology +13

Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial

Paul Van Schil, Rabab Gaafar, Alexander P.W.M. Maat et al. · European Respiratory Journal · 2010 · 242 citations · Full text

Medicine, Oncology, Surgery +9

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

Lee M. Krug, Hedy L. Kindler, Hilary Calvert et al. · The Lancet Oncology · 2015 · 220 citations

Medicine, Oncology, Pharmacotherapy +10

Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975

Fabio Efficace, Andrew Bottomley, Egbert F. Smit et al. · Annals of Oncology · 2006 · 184 citations

Medicine, Oncology, Palliative Care +11